Regulatory snapshots, including drug submissions and approvals, clinical trial approvals and other regulatory decisions and designations in Asia-Pacific, including: Ascentage, Ascletis, Astellas, Astrazeneca, Biovaxys Technology, Direct Biologics, Gtreebnt, Humanigen, Kyowa Kirin, Levena, Mabpharm, Moderna, Oblato, Organicell Regenerative Medicine, Rarestone, Regeneron, Sanofi, Sinovac, Sorrento, Swedish Orphan Biovitrum, Yisheng.